关于这一集
While the cell and gene therapy space represents one of the most exciting therapeutic frontiers in modern biopharma by offering highly personalized, transformative treatments, the sector still faces significant hurdles before it can achieve widespread commercialization. From steep manufacturing costs and a lack of standardization to persistent inefficiencies in scaling production, the road to maturity remains complex.
In this episode of Off Script: A Pharma Manufacturing Podcast, we spoke with Sharon Anderson, VP of Scientific Affairs, Alliance for Regenerative Medicine, about what’s driving progress in CGT manufacturing and where the industry is still lagging.
英语
美国
文字稿 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
本播客中的其他单集
Single-use technologies have reshaped biopharma manufacturing facility design, capacity strategy, and flexibility over the past decade. The industry has expanded with a growing range of targeted therapies and emerging modalities, which has led to manufacturers adopting single-use systems to meet ...
Sterile ophthalmic manufacturing is facing growing demand as more preservative-free therapies move through development, while manufacturers also contend with increasingly stringent expectations around contamination control, inspection, and quality. Blow-fill-seal (BFS) technology offers a closed,...
Researchers have developed a new sensor-enabled bioreactor that uses machine learning technology for improved enzyme production. This advanced technology—created by researchers at Iowa State University and Novonesis, with funding by BioMADE—pairs continuous monitoring with AI-guided control to gi...
The demands on pharmaceutical manufacturing quality teams are growing as they manage larger volumes of data driven by increasingly complex therapies and evolving regulatory expectations. In response, artificial intelligence is emerging as a powerful tool to help quality professionals synthesize i...
Radiopharmaceuticals are a rapidly growing area of oncology, fueled by advances in targeted therapies and expanding product pipelines. But bringing these therapies from development to commercialization presents unique manufacturing challenges, from isotope supply and specialized GMP facilities to...
免责声明: 本页面嵌入的播客和封面图片来自 Pharma Manufacturing，归其所有者所有，与 Listen Notes, Inc. 无关联，也未获得 Listen Notes, Inc. 背书。
